Literature DB >> 17509004

Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.

Celeste B L Man1, Patrick Kwan, Larry Baum, Evelyn Yu, K M Lau, Alice S H Cheng, Margaret H L Ng.   

Abstract

A previous study conducted in Taiwan found a 100% association between HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome (SJS) in Han Chinese subjects, with an extremely high odds ratio compared with carbamazepine-tolerant subjects (odds ratio = 2,504). We examined this association in 24 Hong Kong Han Chinese subjects who had cutaneous adverse reactions induced by different antiepileptic drugs (AEDs). They were matched with 48 AED-tolerant controls. HLA-B*1502 was associated with severe cutaneous reactions (SCR) induced by AEDs, which included carbamazepine, phenytoin, and lamotrigine (p = 0.001, odds ratio = 17.6), but was not associated with maculopapular exanthema (MPE) (p = 0.32). Further studies in larger samples of ethnically matched subjects should be conducted to confirm the findings. Identification of genetic polymorphisms predisposing to development of AED-induced SCR offers the possibility of avoiding these high-risk drugs in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509004     DOI: 10.1111/j.1528-1167.2007.01022.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  107 in total

1.  The impact of pharmacogenetics in the treatment of allergic disease and asthma.

Authors:  Bridgette L Jones
Journal:  Mo Med       Date:  2011 Sep-Oct

2.  Carbamazepine hypersensitivity: progress toward predicting the unpredictable.

Authors:  Barry E Gidal
Journal:  Epilepsy Curr       Date:  2011-11       Impact factor: 7.500

3.  The Art of Managing Conversions between Antiepileptic Drugs: Maximizing Patient Tolerability and Quality of Life.

Authors:  Erik K St Louis
Journal:  Pharmaceuticals (Basel)       Date:  2010-09-01

4.  Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.

Authors:  Gokhan Okan; Serpil Yaylaci; Onder Peker; Sabahattin Kaymakoglu; Murat Saruc
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

5.  Of race, ethnicity, and rash: the genetics of antiepileptic drug-induced skin reactions.

Authors:  John W Miller
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

6.  [Not Available].

Authors:  Josiane Bégin; Marianne Guay; Stéphanie Ricard; Maxime Doré; Anne-Marie Mansour
Journal:  Can Pharm J (Ott)       Date:  2013-09

7.  Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.

Authors:  Robert L Davis; Mia A Gallagher; Maryam M Asgari; Melody J Eide; David J Margolis; Eric Macy; James K Burmester; Nandini Selvam; Joseph A Boscarino; Lee F Cromwell; Heather S Feigelson; Jennifer L Kuntz; Pamala A Pawloski; Robert B Penfold; Marsha A Raebel; Gayathri Sridhar; Ann Wu; Lois A La Grenade; Michael A Pacanowski; Simone P Pinheiro
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-24       Impact factor: 2.890

8.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

9.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

Authors:  P Brent Ferrell; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

10.  Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.

Authors:  Rosa Chan; Chun-Yu Wei; Yuan-Tsong Chen; Leslie Z Benet
Journal:  AAPS J       Date:  2016-03-07       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.